US biotech Gilead Sciences (Nasdaq: GILD) said on Wednesday that it has submitted a request to the US Food and Drug Administration to rescind the orphan drug designation it was granted for the investigational antiviral remdesivir for the treatment of COVID-19 and is waiving all benefits that accompany the designation.
Advocates have voiced concern that the FDA's decision to grant the Orphan status paves the way for Gilead to charge a high price for remdesivir, and could keep lower-priced generic versions of the med off the market for several years.
According to US media reports, which The Pharma Letter was unable to confirm as of this publication, the FDA has agreed to Gilead’s request and has withdrawn the designation.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze